ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75:494-503.e496.
6. Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98:484-489.
7. Drucker AM, Wang AR, Qureshi AA. Research gaps in quality of life and economic burden of atopic dermatitis: the National Eczema Association burden of disease audit. JAMA Dermatol. 2016;152:873-874.
8. Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821-838.
9. Yosipovitch G, Simpson EL, Bushmakin AG, et al. Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS). Itch. 2018;3:e13.
10. Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316-1321.
11. Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019;181:80-87.
12. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263-292.
13. Patel N, Feldman SR. Adherence in atopic dermatitis. Adv Exp Med Biol. 2017;1027:139-159.
14. Spielman SC, LeBovidge JS, Timmons KG, et al. A review of multidisciplinary interventions in atopic dermatitis. J Clin Med. 2015;4:1156-1170.
15. Oussedik E, Cline A, Su JJ, et al. Accountability in patient adherence. Patient Prefer Adherence. 2019;13:1511-1517.
16. Lin Y. Robust inference for responder analysis: innovative clinical trial design using a minimum p-value approach. Contemp Clin Trials Commun. 2016;3:65-69.
6. Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018;98:484-489.
7. Drucker AM, Wang AR, Qureshi AA. Research gaps in quality of life and economic burden of atopic dermatitis: the National Eczema Association burden of disease audit. JAMA Dermatol. 2016;152:873-874.
8. Paller A, Jaworski JC, Simpson EL, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am J Clin Dermatol. 2018;19:821-838.
9. Yosipovitch G, Simpson EL, Bushmakin AG, et al. Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS). Itch. 2018;3:e13.
10. Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316-1321.
11. Silverberg JI, Simpson EL, Ardeleanu M, et al. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. Br J Dermatol. 2019;181:80-87.
12. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263-292.
13. Patel N, Feldman SR. Adherence in atopic dermatitis. Adv Exp Med Biol. 2017;1027:139-159.
14. Spielman SC, LeBovidge JS, Timmons KG, et al. A review of multidisciplinary interventions in atopic dermatitis. J Clin Med. 2015;4:1156-1170.
15. Oussedik E, Cline A, Su JJ, et al. Accountability in patient adherence. Patient Prefer Adherence. 2019;13:1511-1517.
16. Lin Y. Robust inference for responder analysis: innovative clinical trial design using a minimum p-value approach. Contemp Clin Trials Commun. 2016;3:65-69.
AUTHOR CORRESPONDENCE
Liza Takiya PharmD BCPS FCCP liza.takiya@pfizer.com
